- Home
- GNLX vs TIL Comparison
GNLX vs TIL Comparison
Compare GNLX & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- TIL
- Stock Information
- Founded
- GNLX 2001
- TIL 2018
- Country
- GNLX United States
- TIL United States
- Employees
- GNLX N/A
- TIL N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- TIL Health Care
- Exchange
- GNLX Nasdaq
- TIL Nasdaq
- Market Cap
- GNLX 112.5M
- TIL 230.1M
- IPO Year
- GNLX 2023
- TIL 2021
- Fundamental
- Price
- GNLX $3.44
- TIL $24.49
- Analyst Decision
- GNLX Strong Buy
- TIL Buy
- Analyst Count
- GNLX 4
- TIL 5
- Target Price
- GNLX $17.75
- TIL $119.00
- AVG Volume (30 Days)
- GNLX 153.5K
- TIL 315.0K
- Earning Date
- GNLX 08-13-2025
- TIL 08-12-2025
- Dividend Yield
- GNLX N/A
- TIL N/A
- EPS Growth
- GNLX N/A
- TIL N/A
- EPS
- GNLX N/A
- TIL N/A
- Revenue
- GNLX N/A
- TIL N/A
- Revenue This Year
- GNLX N/A
- TIL N/A
- Revenue Next Year
- GNLX N/A
- TIL N/A
- P/E Ratio
- GNLX N/A
- TIL N/A
- Revenue Growth
- GNLX N/A
- TIL N/A
- 52 Week Low
- GNLX $1.60
- TIL $9.70
- 52 Week High
- GNLX $5.89
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- GNLX 65.71
- TIL 47.69
- Support Level
- GNLX $2.80
- TIL $21.80
- Resistance Level
- GNLX $3.61
- TIL $26.91
- Average True Range (ATR)
- GNLX 0.22
- TIL 3.52
- MACD
- GNLX 0.05
- TIL -0.37
- Stochastic Oscillator
- GNLX 80.23
- TIL 35.14
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.